Effect of dendrimer on entrapment and release of bioactive from liposomes

Khopade, A. J.; Caruso, Frank; Tripathi, Pushpendra Kumar; Nagaich, Surekha; Jain, Narendra Kumar

doi:10.1016/s0378-5173(01)00901-2

Cited by 85 publications

(56 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The complex incorporated into liposome (HePC:EPC:SA) 10:10:0.1 (molar ratio), showed a delayed release of doxorubicin that is crucial for reducing its adverse effects and increasing its therapeutic index (Papagiannaros et al, 2005). These findings were very close to those published for the acidic drug methotrexete (Khopade et al, 2002), where claimed that the release was lowered from a dendrimeric liposomal formulation. In a recently published work by our team new synthetic generation 1 and 2 polyetherpolyester dendrimers (G1 and G2) were incorporated into liposomes consisting of dioleicphosphatidylcholine/ dipalmitoyphosphatidylglycerol (DOPC/DPPG) (Gardikis et al, 2010).…”

Section: Final Characterization F(chi-) or (Hy-)-amcddnsssupporting

confidence: 80%

Advanced drug delivery nanosystems (aDDnSs): a mini-review

Demetzos¹,

Pippa²

2013

Drug Delivery

View full text Add to dashboard Cite

Significant progress has been made in nanoscale drugs and delivery systems employing diverse chemical formulations to facilitate the rate of drug delivery and to improve its pharmacokinetics. Biocompatible nanomaterials have been used as biological markers, contrast agents for imaging, healthcare products, pharmaceuticals, drug-delivery systems as well as in detection, diagnosis and treatment of various types of diseases. The classification of drug delivery nanosystems (DDnSs) is a crucial issue and fundamental efforts on this subject are missing from the literature. This article deals with the classification of DDnSs with a modulatory controlled release profile (MCR) denoted as modulatory controlled release nanosystems (MCRnSs). Conventional (c) and advanced (a) DDnSs are denoted by the acronyms cDDnSs and aDDnSs, and can be composed of a single or more than one biomaterials, respectively. The classification was based on their characteristics such as: surface functionality (f), the nature of biomaterials used and the kind of interactions between biomaterials. The aDDnSs can be classified as hybridic (Hy-) or chimeric (Chi-) based on the nature -same or different respectively -of biomaterials and inorganic materials used. The nature of the elements used for producing advanced biomaterials is of great importance and medicinal chemistry contributes effectively to the production of aDDnSs.

show abstract

Section: Final Characterization F(chi-) or (Hy-)-amcddnsssupporting

confidence: 80%

Advanced drug delivery nanosystems (aDDnSs): a mini-review

Demetzos¹,

Pippa²

2013

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…6 Dendritic architecture and uniformly positioned functionality have been recently reported to carry the anti-inflammatory drug indomethacin for its transdermal delivery as well as anticancer drugs (eg, 6-mercaptopurine). 7,8 Recent studies reported investigation on the effect of 4.0 generation (G) PAMAM dendrimer present in an anionic phospholipid composition, consisting of hydrogenated soyaphosphotidylcholine, cholesterol, dicetylphosphate, and poly(ethylene glycol)-derivatized phosphotidylethnolamine, on the hydration and liquid crystalline structure formation. 9 Flurbiprofen (FB), a phenylpropionic acid derivative with analgesic and anti-inflammatory action, is widely used in the treatment of rheumatoid arthritis and other rheumatic disorders.…”

Section: Introductionmentioning

confidence: 99%

Poly(amidoamine) (PAMAM) dendritic nanostructures for controlled sitespecific delivery of acidic anti-inflammatory active ingredient

et al. 2005

View full text Add to dashboard Cite

The purpose of the investigation was to evaluate the potential of polyamidoamine (PAMAM) dendrimer as nanoscale drug delivery units for controlled release of water insoluble and acidic anti-inflammatory drug. Flurbiprofen (FB) was selected as a model acidic anti-inflammatory drug. The aqueous solutions of 4.0 generation (G) PAMAM dendrimer in different concentrations were prepared and used further for solubilizing FB. Formation of dendrimer complex was characterized by Fourier transform infrared spectroscopy. The effect of pH on the solubility of FB in dendrimer was evaluated. Dendrimer formulations were further evaluated for in vitro release study and hemolytic toxicity. Pharmacokinetic and biodistribution were studied in male albino rats. Efficacy of dendrimer formulation was tested by carrageenan induced paw edema model. It was observed that the loaded drug displayed initial rapid release (more than 40% till 3rd hour) followed by rather slow release. Pharmacodynamic study revealed 75% inhibition at 4th hour that was maintained above 50% till 8th hour. The mean residence time (MRT) and terminal half-life (THF) of the dendritic formulation increased by 2-fold and 3-fold, respectively, compared with free drug. Hence, with dendritic system the drug is retained for longer duration in the biosystem with 5-fold greater distribution. It may be concluded that the drug-loaded dendrimers not only enhanced the solubility but also controlled the delivery of the bioactive with localized action at the site of inflammation.

show abstract

“…The percentage hemolysis was calculated for each sample by considering that 100% hemolysis occurred in water. 17,18,21 In Vitro Release…”

Section: Hemolytic Studymentioning

confidence: 99%